Select your Market

Global
Africa
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo
Congo Democratic Republic
Djibouti
Egypt
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Ivory Coast
Kenya
Lesotho
Liberia
Libya
Madagascar
Malawi
Mauritania
Mauritius
Morocco
Mozambique
Namibia
Niger
Nigeria
Reunion Islands
Rwanda
Saint Helena
São Tomé and Príncipe
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
Sudan
Swaziland
Tanzania
Togo
Tunisia
Uganda
Zambia
Zimbabwe
Asia
Bahrain
Bangladesh
China, mainland
India
Indonesia
Iran
Iraq
Israel
Japan
Jordan
Kuwait
Lebanon
Malaysia
Oman
Palestine
Philippines
Qatar
Saudi Arabia
Singapore
South Korea
Syria
Taiwan
Thailand
Turkey
United Arab Emirates
Vietnam
Yemen
Europe
Albania
Austria
Baltic Region
Belarus
Belgium
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Luxembourg
Netherlands
North Macedonia
Norway
Poland
Portugal
Romania
Russian Federation
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Türkiye
Ukraine
United Kingdom
Latin America
Argentina
Aruba
Bahamas
Barbados
Belize
Bolivia
Brazil
Central America
Chile
Colombia
Costa Rica
Cuba
Curacao-NL Antillen
Ecuador
El Salvador
Guatemala
Haiti
Honduras
Jamaica
Mexico
Nicaragua
Panama
Paraguay
Perú
República Dominicana
Trinidad and Tobago
Uruguay
Venezuela
North America
Canada
United States of America
Oceania
Australia
New Zealand
Global
  1. Press Releases

2026 Future Insight Prize Goes to Spear’s Vasilis Ntziachristos

The € 300,000 research grant award recognizes Ntziachristos’ pioneering work in enabling non-invasive and continuous monitoring of human biology.

Subscribe
23 Jun 2026 | Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today awarded the 2026 Future Insight Prize to Prof. Dr. Vasilis Ntziachristos, representing optoacoustic and fluorescence solutions company Spear, Munich, Germany, a spin-off of Helmholtz Munich and Technical University of Munich. Ntziachristos is also the Chair of Biological Imaging at the Technical University of Munich as well as Director of Bioengineering and Director of the Institute of Biological and Medical Imaging at the Helmholtz Centre in Munich. The € 300,000 research grant award recognizes Ntziachristos’ pioneering work in enabling non-invasive and continuous monitoring of human biology.

“This year’s prize to Vasilis Ntziachristos recognizes a scientist who has advanced a fundamentally new approach to measuring the human body. His work combines light and sound in a way that overcomes long-standing limits of sensing,” said Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, Darmstadt, Germany. “This opens up access to a new layer of biological understanding. It could allow us to detect early metabolic changes before symptoms appear. At our company, we pursue the same goal: creating previously unseen combinations of science and technology, and turning them into real-world applications.”

“I am grateful to see the support from Merck KGaA, Darmstadt, Germany, for our pioneering research,” said Vasilis Ntziachristos. “Our goal has always been to observe biological processes in ways that were not previously possible. By expanding the depth, quality and dimensionality of non-invasive measurement, we aim to support earlier disease detection, more effective therapies and better outcomes for patients.”

Ntziachristos’ research has fundamentally advanced biomedical imaging by introducing optoacoustic technologies that combine light and sound to visualize tissue structures and functions with unprecedented resolution and depth. Unlike conventional optical sensing methods, optoacoustic approaches enable direct measurement of biological signals such as microcirculation, oxygenation and metabolic activity. These capabilities address a fundamental limitation of current sensing approaches by allowing for non-invasive observation of a large number of biological processes that define health and disease. By translating these advances into sensor technologies, the awarded research aims to make possible a new class of health systems capable of capturing multiple biomarkers simultaneously and continuously over time.

Since 2018, the Future Insight Prize has honored outstanding scientists whose work has the potential to enable groundbreaking innovations for humanity. The 2027 Future Insight Prize will focus on the visionary goal of an AI-powered robotic scientist – a fully autonomous system capable of generating hypotheses, conducting experiments and accelerating discovery through self-learning cycles. Members of the global scientific community who wish to suggest outstanding candidates for the 2027 prize can e-mail the jury. The award will be presented at Curious2027 – Future Insight Conference in Heidelberg, Germany.

Downloads

For more information, contact Gangolf Schrimpf
+49 151 1454-9591

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck KGaA, Darmstadt, Germany, generated sales of € 21.1 billion in 65 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.emdgroup.com/subscribe to register for your online, change your selection or discontinue this service.

Related News

  1. Press Releases

    MilliporeSigma Appoints New Heads of Discovery Solutions and Strategy & ...

    MilliporeSigma appoints Clara Sattler de Sousa e Brito and Robert Machinek to strengthen leadership team.

    2026/06/08